Navigation Links
IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at,2007 ASCO Annual Meeting

New York .

Forward-Looking Statements

This press release includes and the presentation described in this press release will include forward-looking statements that reflect management's current views of future events including statements regarding the phase II UVIDEM study and the potential for UVIDEM as a treatment for melanoma and the phase II EP-2101 study and the potential for EP-2101 as a treatment for NSCLC, and review of the submissions for marketing approval of JUNOVAN by the FDA and the EMEA. Actual results may differ materially from the forward-looking statements due to a number of important factors, including, but not limited to, the timing of the FDA's and EMEA's review of the submissions for marketing approval, the ability of the Company to respond to questions raised by the FDA and EMEA in a satisfactory manner, the time needed to respond to any issues raised by the FDA and EMEA with regard to regulatory submissions for JUNOVAN, although the FDA is not bound by the decision of any advisory panel, the possible negative impact that the opinion of the FDA's Oncologic Drug Advisory Committee that the results of the Company's Phase III trial do not provide substantial evidence of effectiveness of JUNOVAN in the treatment of patients with non-metastatic, resectable osteosarcoma receiving combination chemotherapy would have upon the determination by the FDA whether to approve the marketing application for JUNOVAN, which would have a material and adverse affect on IDM's business, the possibility that regulatory authorities may not consider preclinical and early clinical development work conducted by Ciba-Geigy and efficacy data from the Phase III trial conducted by Children's Oncology Group as adequate for their assessment of JUNOVAN, which may cause delays in review, may result in the regulatory authorities requiring the Company to conduct additional clinical trials, or may result in a determination by the regulatory authorities that the data do
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
(Date:7/30/2015)... Calif. , July 30, 2015  NanoSmart ... drug delivery platforms, has received Orphan Drug Designation ... a second drug product that uses NanoSmart,s proprietary ... formulation of dactinomycin for the treatment of Ewing,s ... The FDA granted NanoSmart,s Orphan Drug Designation on ...
(Date:7/30/2015)...  Cleave Biosciences today announced that the United ... company a key patent providing the protection of ... This newly issued patent, "Fused pyrimidines and ... allows for claims on the composition of matter ... of p97, a critical enzyme that controls various ...
(Date:7/30/2015)...  Alimera Sciences, Inc. (NASDAQ: ALIM ) (Alimera), ... and commercialization of prescription ophthalmic pharmaceuticals, today announced that ... financial results after the market close on Monday, August ... the same day at 4:30 p.m. ET. ... Officer, and Rick Eiswirth , Chief Operating Officer ...
Breaking Medicine Technology:NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2Alimera Sciences To Release Second Quarter Fiscal Year 2015 Financial Results 2
... , MOUNTAIN VIEW, Calif., Dec. 18 ... of Ruediger Naumann-Etienne to its Board of Directors. , "Rudi ... medical device companies," said Theodore A. Boutacoff, President and CEO ... & Quist followed by CEO/President positions with Diasonics, OEC Medical ...
... Dec. 18 Eli Lilly and Company (NYSE: ... and chief financial officer for Lilly, has assumed expanded responsibilities ... and chief financial officer, effective January 1. , In ... officer of the company and add responsibility for global services, ...
Cached Medicine Technology:Ruediger Naumann-Etienne Appointed to IRIDEX Board of Directors 2Ruediger Naumann-Etienne Appointed to IRIDEX Board of Directors 3Lilly CFO Derica Rice Assumes Expanded Responsibilities, Promoted to Executive Vice President 2
(Date:7/30/2015)... ... 2015 , ... The Mesothelioma Applied Research Foundation (Meso Foundation) ... of 2015’. The bill was introduced in Congress yesterday by Representatives John Katko ... Joe Kennedy (D-MA), and Leonard Lance (R-NJ). The purpose of the bill is ...
(Date:7/30/2015)... ... July 30, 2015 , ... Western University of Health Sciences ... Special Olympics World Games, the largest sports and humanitarian event in the world this ... , The World Games, held July 25 through August 2, 2015, benefited from the ...
(Date:7/30/2015)... FL (PRWEB) , ... July 30, 2015 , ... Between ... according to the Health News Florida on June 17th. Those untreated heroin ... exchange programs to prevent the spread of dirty needles throughout the community. Ultimately Florida’s ...
(Date:7/30/2015)... ... July 30, 2015 , ... Gummy smile surgeon, Dr. Alex ... and surgery, as well as the patented gum depigmentation treatmet. Dr. Farnoosh is a ... with many patients from around the world. , “Like treatment of any other disease ...
(Date:7/30/2015)... NY (PRWEB) , ... July 30, 2015 , ... ... at Mount Sinai Earns National Cancer Institute Designation , The Tisch Cancer Institute ... a National Cancer Institute (NCI)-designated cancer center. TCI joins an elite group of ...
Breaking Medicine News(10 mins):Health News:Bill to Create Patient Registry for Deadly Cancer Introduced in Congress 2Health News:WesternU Makes Big Impact at Special Olympics 2Health News:WesternU Makes Big Impact at Special Olympics 3Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 2Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 3Health News:Gummy Smile Dentist, Alex Farnoosh DMD, is Now Offering Comprehensive Treatment Options for Gummy Smiles 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 3Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 4Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 5Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 6
... It has been proposed by the Ohio-based Cleveland Clinic, ... summer, the services which would benefit Canadians // considering ... The Cleveland clinic houses more than 1,900 scientists and ... the U.S, treating pateints from 80 different countries. ...
... have to wait until areas affected by H5N1 bird ... forces//, according to health officials belonging to the Agriculture ... been confirmed in the eastern province of Nangarhar and ... culling of poultry would be implemented with immediate effect, ...
... also known as ice has resulted in increasing number of ... cases// and they are struggling to deal with the consequences. ... addicts have a psychotic episode. Sydney's St Vincent's Hospital has ... The numbers have surpassed the heroin addicts in Australia. ...
... case of bird flu in Maharashtra has ruffled up chicken ... prices which were stabilizing// , have again plummeted following incidents ... , ,There have been few takers for chicken ... parts of Hyderabad-Karnataka have been hit by bird-flu. The losses ...
... the right dose, vitamin D is important for bone ... several cancers, particularly// colorectal cancer.,To be effective against cancer ... can be dangerous and toxis. Now, research done at ... may be possible to separate the anticancer properties of ...
... football prints and innerwear with net inserts are some ... are experimenting with.,Overall, the trend in lingerie this year ... hint of romance. The seductive undergarments require a little ... with embroidery. The garments aren't so opulent, rather more ...
Cached Medicine News:Health News:Satellite Clinic To Be Set Up in Toronto By Ohio-Based Cleveland Clinic 2Health News:High Demand For Protective Suit in Afghan: Culling Would Have To Wait 2Health News:Anticancer Properties of Vitamin D Revealed 2Health News:Anticancer Properties of Vitamin D Revealed 3Health News:Romantic and discreet trends in lingerie 2
... Eliminate the need for makeshift, modified ... Why waste time gathering parts when your ... need to deliver the utmost in Heliox ... therapy is fast becoming the standard of ...
... has been developing diverse medical ... years. Our medical-surgical products have ... innovation, quality and customer satisfaction. ... the Labtron® line of diagnostic ...
... nebulizer utilizing Vibrating Mesh Technology to ... suffering from Asthma, COPD or other ... product size and handy carrying case ... takes them. Powerful delivery comparable to ...
... deliver particulate humidity in the 3 to ... patients. For your convenience, Thera-Mist® nebulizers may ... sterile water., ,The P30000N, for normal ... with a total flow range of 68-24 ...
Medicine Products: